PEDIATRICS Vol. 108 No. 3 September 2001, pp. 809-811
AMERICAN ACADEMY OF PEDIATRICS:
Screening Examination of Premature Infants for Retinopathy of
Prematurity
This statement revises a previous statement on
screening of premature infants for retinopathy of prematurity
originally published in 1997.
![]()
ABSTRACT
Top
Abstract
Introduction
References
Retinopathy of prematurity (ROP) is a retinal disorder of
low birth weight premature infants potentially leading to blindness in
a small but significant percentage of those infants. The results of the
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group indicated that treatment is associated with a 41%
decrease in the occurrence of posterior retinal traction folds or
detachments and a 19% to 24% decrease in the incidence of blindness
when evaluated 5 years later.1-3 Because of the
sequential nature of the progression of ROP, the proven benefits of
cryotherapy and, more recently, the acceptance of at least equivalent
therapeutic benefit of laser therapy for the same
indications,4-7 standards of practice now demand
carefully timed retinal examinations of at-risk infants by an
ophthalmologist experienced in the examination of preterm infants for
ROP to minimize the risk of visual loss by those infants.
This statement outlines the principles on which a screening program to
detect ROP in infants at risk might be based. The goal of an effective
screening program must be to identify the relatively few preterm
infants who require treatment for ROP from among the much larger number
born each year while minimizing the number of stressful examinations
required for these sick infants. Any screening program designed to
implement an evolving standard of care has inherent defects, such as
overreferral or underreferral, and cannot, by its very nature,
duplicate the precision and rigor of a scientifically based clinical
trial. With that in mind and on the basis of information published thus
far, the sponsoring organizations of this statement suggest the
following guidelines for the United States:
1.
Infants with a birth weight of less than 1500 g or with a
gestational age of 28 weeks or less, as well as selected infants between 1500 and 2000 g with an unstable clinical course who are believed to be at high risk by their attending pediatrician or neonatologist, should have at least 2 fundus examinations performed after pupillary dilation using binocular indirect ophthalmoscopy to
detect ROP. One examination is sufficient only if it unequivocally shows the retina to be fully vascularized bilaterally.
2.
Examination for ROP should be performed by an ophthalmologist with
sufficient regular experience and knowledge in the examination of
preterm infants for ROP to identify the location and sequential retinal
changes in this disorder using binocular indirect ophthalmoscopy. The
location and sequential retinal changes, if any, should be recorded
using the International Classification of Retinopathy of
Prematurity.8
3.
The first examination should normally be performed between 4 and 6 weeks of chronologic (postnatal) age or, alternatively, within the 31st
to 33rd week of postconceptional or postmenstrual age (gestational age
at birth plus chronologic age), whichever is later, as determined by
the infant's attending pediatrician or neonatologist. If using the
postconceptional age guideline, examinations are generally not needed
in the first 4 weeks after birth. The timing of the initial screening
examination may be adjusted appropriately on the basis of other
reliable data, such as local incidence and onset of ROP or the presence
of other recognized risk factors.8,9 The initial screening
examination and subsequent examinations should be timed to permit
sufficient time for treatment, including, any extra time required for
transfer to another facility for treatment, if necessary. Treatment
should generally be accomplished within 72 hours of determination of the presence of threshold 1 ROP to minimize the risk of retinal detachment before treatment.
4.
Scheduling of follow-up examinations at the recommendation of the
examining ophthalmologist is best determined by the findings at the
first examination using the International Classification of
Retinopathy of Prematurity. For example, if the retinal
vasculature is immature and extends into zone II but no retinopathy is
present, follow-up examination should be planned at approximately 2- to 3-week intervals until normal vascularization proceeds to zone III (ie,
in the nasal periphery, there is no retinopathy and normal vessels are
present within 1 disk diameter of the ora serrata).
5.
Once an infant has been determined on first examination to be at risk
for ROP, the following schedule is suggested:
A.
Infants with ROP that may soon progress to threshold ROP should be
examined at least weekly. These include:
1.
Any infant with ROP less than threshold in zone I
2.
Infants with ROP in zone II, including:
a)
those with stage 3 ROP without plus disease (defined as posterior pole
dilation and tortuosity of the retinal vessels);
b)
those with stage 2 ROP with plus disease; and
c)
those with stage 3 ROP with plus disease not yet extensive enough to
justify ablative surgery.
B.
Infants with less severe ROP in zone II should be examined at 2-week
intervals. Those without ROP but with incomplete vascularization in
zone I should be seen at 1- to 2-week intervals until retinal vascularization has reached zone III or until threshold conditions are
reached.
C.
If the retinal vascularization is incomplete in zone II but no ROP is
detected, follow-up examination should be planned at approximately 2- to 3-week intervals until vascularization proceeds into zone III.
D.
Retinas with incomplete vascularization only in zone III usually mature
completely; ROP in zone III normally regresses (involutes) without
adverse consequences. However, the finding of normal vascularization in
zone III is unusual in the initial examination of very low gestational
age infants. In cases in which zone III vascular maturation seems to be
present on initial examination of very low birth weight infants, this
finding should be verified by at least 1 repeat examination within 2 to
3 weeks.
6.
Infants reaching threshold 1 disease (stage 3 ROP in zone I or II in 5 or more continuous clock hours or 8 cumulative clock hours [30°
sectors] with plus disease [posterior retinal vessel dilation and
tortuosity]) should receive ablative therapy for at least 1 eye within
72 hours of diagnosis, generally before the onset of retinal
detachment. Stage 3 ROP with vascularization in zone I or borderline
zone I to II may appear different from purely zone II stage 3 disease
in that proliferation may appear flat, only appearing to be
significantly elevated when it has become extremely severe. In view of
this difficulty in distinguishing between stages 2 and 3 in posterior
regions, infants with suspected stage 3 ROP in zone I or border zone I
to II with plus disease should be examined especially carefully to
determine if they meet the threshold criteria noted above.
7.
Parents of infants with ROP should be informed of the nature and
possible consequences of this disorder throughout the infant's hospital stay, beginning at the time of first diagnosis and continuing on an ongoing basis with updates on its progression during
hospitalization.
8.
Responsibility for examination and follow-up of infants at risk for ROP
must be carefully defined by each neonatal intensive care unit.
Unit-specific criteria for examination for ROP should be established
for each neonatal intensive care unit by consultation and agreement
between neonatology and ophthalmology services. These criteria should
be recorded and should automatically trigger scheduled ophthalmology
examinations. If hospital discharge or transfer to another neonatal
unit or hospital is contemplated before retinal maturation into zone
III has taken place, the availability of appropriate follow-up
ophthalmologic examination must be ensured, and specific arrangement
for that examination must be made before such discharge or transfer
occurs. The transferring primary physician should have the
responsibility of communicating orally and in writing what eye
examinations are needed and their required timing to the infant's new
primary physician. The new primary physician should ascertain the
current ocular examination status of the infant from the record and
through communication with the transferring physician so that any
necessary examinations by an ophthalmologist with regular experience
and knowledge of the examination of preterm infants for ROP
can be arranged promptly at the receiving facility. If responsibility
for arranging follow-up after discharge is delegated to the parents, it
must be clearly understood by the parents that blindness is a possible
outcome, that there is a critical time window to be met if
treatment is to be successful, and that timely follow-up examination is
essential to successful treatment; this information should be
transmitted to the parents orally and in writing. If such arrangements
for follow-up after transfer or discharge cannot be made, the infant
should not be transferred or discharged.
These recommendations replace the previous American Academy of
Pediatrics statement on ROP,10 are evolving, and may be
modified as additional ROP risk factors, treatment, and long-term
outcomes are known.
Retinopathy of Prematurity Subcommittee, 1997-2001
Walter M. Fierson, MD, Chairperson
Earl A. Palmer, MD
Robert A. Petersen, MD
Dale L. Phelps, MD
Richard A. Saunders, MD
Section on Ophthalmology, 2000-2001
Gary T. Denslow, MD, MPH, Chairperson
Jay Bernstein, MD
Edward G. Buckley, MD
Allan M. Eisenbaum, MD
George S. Ellis, Jr, MD
Howard L. Freedman, MD
Steven J. Lichtenstein, MD
Consultant
Harold P. Koller, MD, Immediate Past Chairperson
Staff
Stephanie Mucha
American Association for Pediatric Ophthalmology and Strabismus
American Academy of Ophthalmology
![]()
INTRODUCTION
Top
Abstract
Introduction
References
| |
FOOTNOTES |
|---|
The recommendations in this statement do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
| |
ABBREVIATIONS |
|---|
ROP, retinopathy of prematurity.
| |
REFERENCES |
|---|
|
|
|---|
-
Cryotherapy for Retinopathy of Prematurity Cooperative Group
Multicenter trial of cryotherapy for retinopathy of prematurity:
preliminary results.
Arch Ophthalmol
1988;
106:471-479
[Abstract/Free Full Text] -
Cryotherapy for Retinopathy of Prematurity Cooperative Group
Multicenter trial of cryotherapy for retinopathy of prematurity. 3 1/2-year outcome
structure and function.
Arch Ophthalmol
1993;
111:339-344 [Abstract/Free Full Text] -
Cryotherapy for Retinopathy of Prematurity Cooperative Group
Multicenter trial of cryotherapy for retinopathy of prematurity.
Snellen visual acuity and structural outcome at 5 1/2 years after
randomization.
Arch Ophthalmol
1996;
114:417-424
[Abstract/Free Full Text] - McNamara JA, Tasman W, Brown GC, Federman JL Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology 1991; 98:576-580 [Medline]
- Hunter DG, Repka MX Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology 1993; 100:238-244 [Medline]
- Laser ROP Study Group Laser therapy for retinopathy of prematurity. Arch Ophthalmol 1994; 112:154-56
-
Iverson DA,
Trese MT,
Orgel IK,
Williams GA
Laser photocoagulation for
threshold retinopathy of prematurity.
Arch Ophthalmol
1991;
109:1342-1343
[Abstract/Free Full Text] -
Committee for the Classification of Retinopathy of Prematurity
An
international classification of retinopathy of prematurity.
Arch
Ophthamol
1984;
102:1130-1134
[Abstract/Free Full Text] - Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity, 1989-1997. Pediatrics. 1999;104(3). Available at: URL: http://www.pediatrics.org/cgi/content/full/104/3/e26
- American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 1997;100:273. Ophthalmology 1997; 104:888-889 [Medline]
| |
RELATED READINGS |
|---|
-
Hutchinson AK,
Saunders RA,
O'Neil JW,
Lovering A,
Wilson ME
Timing of initial screening examination in retinopathy of prematurity.
Arch Ophthalmol
1998;
116:608-612
[Abstract/Free Full Text] - Palmer EA, Flynn JT, Hardy RJ, Incidence and early course of retinopathy of prematurity. Ophthalmology 1991; 98:1628-1640 [Medline]
Pediatrics (ISSN 0031 4005). Copyright ©2001 by the American Academy of Pediatrics
The following policy statement is a revision:
- Screening Examination of Premature Infants for Retinopathy of Prematurity
- , , , and
Pediatrics 117: 572-576.[Full Text]
This article has been cited by other articles:
![]() |
V. Praveen, R. Vidavalur, T. S. Rosenkrantz, and N. Hussain Infantile Hemangiomas and Retinopathy of Prematurity: Possible Association Pediatrics, March 1, 2009; 123(3): e484 - e489. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Murakami, A Jain, R A Silva, E M Lad, J Gandhi, and D M Moshfeghi Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): 12-month experience with telemedicine screening Br J Ophthalmol, November 1, 2008; 92(11): 1456 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Karkhaneh, S Z Mousavi, M Riazi-Esfahani, S A Ebrahimzadeh, R Roohipoor, M Kadivar, L Ghalichi, S F Mohammadi, and M R Mansouri Incidence and risk factors of retinopathy of prematurity in a tertiary eye hospital in Tehran Br J Ophthalmol, November 1, 2008; 92(11): 1446 - 1449. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Jackson, K. E. Scott, J. Graff Zivin, D. A. Bateman, J. T. Flynn, J. D. Keenan, and M. F. Chiang Cost-Utility Analysis of Telemedicine and Ophthalmoscopy for Retinopathy of Prematurity Management Arch Ophthalmol, April 1, 2008; 126(4): 493 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Chen, X-x Li, H Yin, C Gilbert, J-h Liang, Y-r Jiang, M-w Zhao, and Beijing ROP Survey Group Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing, China Br J Ophthalmol, March 1, 2008; 92(3): 326 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Chiang, L. Wang, M. Busuioc, Y. E. Du, P. Chan, S. A. Kane, T. C. Lee, D. J. Weissgold, A. M. Berrocal, O. Coki, et al. Telemedical Retinopathy of Prematurity Diagnosis: Accuracy, Reliability, and Image Quality Arch Ophthalmol, November 1, 2007; 125(11): 1531 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Kemper and D. K. Wallace Neonatologists' Practices and Experiences in Arranging Retinopathy of Prematurity Screening Services Pediatrics, September 1, 2007; 120(3): 527 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
M F Chiang, J Starren, Y E Du, J D Keenan, W M Schiff, G R Barile, J Li, R A Johnson, D J Hess, and J T Flynn Remote image based retinopathy of prematurity diagnosis: a receiver operating characteristic analysis of accuracy Br J Ophthalmol, October 1, 2006; 90(10): 1292 - 1296. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Robaei, A. Kifley, G. A. Gole, and P. Mitchell The impact of modest prematurity on visual function at age 6 years: findings from a population-based study. Arch Ophthalmol, June 1, 2006; 124(6): 871 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Wang, E. A. McGlynn, R. H. Brook, C. H. Leonard, R. E. Piecuch, S. I. Hsueh, and M. A. Schuster Quality-of-Care Indicators for the Neurodevelopmental Follow-up of Very Low Birth Weight Children: Results of an Expert Panel Process. Pediatrics, June 1, 2006; 117(6): 2080 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Chiang, J. D. Keenan, J. Starren, Y. E. Du, W. M. Schiff, G. R. Barile, J. Li, R. A. Johnson, D. J. Hess, and J. T. Flynn Accuracy and reliability of remote retinopathy of prematurity diagnosis. Arch Ophthalmol, March 1, 2006; 124(3): 322 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Chen and X Li Characteristics of severe retinopathy of prematurity patients in China: a repeat of the first epidemic? Br J Ophthalmol, March 1, 2006; 90(3): 268 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
Section on Ophthalmology, American Academy of Pediatrics, American Academy of Ophthalmology, and American Association for Pediatric Ophthalmology a Screening Examination of Premature Infants for Retinopathy of Prematurity Pediatrics, February 1, 2006; 117(2): 572 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lubetzky, C. Stolovitch, S. Dollberg, F. B. Mimouni, M. Salomon, and D. Mandel Nucleated Red Blood Cells in Preterm Infants With Retinopathy of Prematurity Pediatrics, November 1, 2005; 116(5): e619 - e622. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gilbert, A. Fielder, L. Gordillo, G. Quinn, R. Semiglia, P. Visintin, A. Zin, and on behalf of the International NO-ROP Group Characteristics of Infants With Severe Retinopathy of Prematurity in Countries With Low, Moderate, and High Levels of Development: Implications for Screening Programs Pediatrics, May 1, 2005; 115(5): e518 - e525. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Towers Retinopathy of Prematurity Screening after NICU Discharge or Transfer AAP Grand Rounds, February 1, 2005; 13(2): 15 - 16. [Full Text] [PDF] |
||||
![]() |
L. R. Blackmon Improving quality, reducing liability risk in neonatal care AAP News, November 1, 2004; 25(5): 248 - 248. [Full Text] [PDF] |
||||
![]() |
T. E. Young Pharmacology Review: Topical Mydriatics: The Adverse Effects of Screening Examinations for Retinopathy of Prematurity NeoReviews, June 1, 2003; 4(6): e163 - 166. [Full Text] [PDF] |
||||
![]() |
J. D. Reynolds, V. Dobson, G. E. Quinn, A. R. Fielder, E. A. Palmer, R. A. Saunders, R. J. Hardy, D. L. Phelps, J. D. Baker, M. T. Trese, et al. Evidence-Based Screening Criteria for Retinopathy of Prematurity: Natural History Data From the CRYO-ROP and LIGHT-ROP Studies Arch Ophthalmol, November 1, 2002; 120(11): 1470 - 1476. [Abstract] [Full Text] [PDF] |
||||
![]() |
G E Quinn What do you do about ROP screening in "big" babies? Br J Ophthalmol, October 1, 2002; 86(10): 1072 - 1073. [Full Text] |
||||
![]() |
L Andruscavage and D J Weissgold Screening for retinopathy of prematurity Br J Ophthalmol, October 1, 2002; 86(10): 1127 - 1130. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||










